In patients with Huntington's Disease, intra-striatal NGF administration is neurotrophic solely for cholinergic neurons, while transport facilitated by genetically engineered cells has shown improvements in both cholinergic and GABAergic networks. This evidence concerns the gene NGF and juvenile Huntington disease.